Pics 6: Lymphoid/PCD Flashcards by Victoria DeVito

Q

HL subtypes and frequency of each

A

How well did you know this?

1

Not at all

2

3

4

5

Perfectly

Q

Difference between cHL and NLPHL
New name for NLPHL

A

NLPBCL

How well did you know this?

1

Not at all

2

3

4

5

Perfectly

Q

Early stage HL: prognostic markers
GHSG vs EORTC

A

How well did you know this?

1

Not at all

2

3

4

5

Perfectly

Q

Prognostic in Advanced stage cHL

A

How well did you know this?

1

Not at all

2

3

4

5

Perfectly

Q

PET Deauville scores

A

How well did you know this?

1

Not at all

2

3

4

5

Perfectly

Q

Early stage cHL, favourable
4 options, which trials

A

How well did you know this?

1

Not at all

2

3

4

5

Perfectly

Q

Early stage HL, unfavourable
4 options, trials

A

How well did you know this?

1

Not at all

2

3

4

5

Perfectly

Q

Advanced stage cHL
2 main options in 2024
What were the prior 3 options

A

How well did you know this?

1

Not at all

2

3

4

5

Perfectly

Q

HL conclusions 1

A

How well did you know this?

1

Not at all

2

3

4

5

Perfectly

Q

HL early stage conclusions

A

How well did you know this?

1

Not at all

2

3

4

5

Perfectly

Q

HL advanced stage conclusions, R/R

A

How well did you know this?

1

Not at all

2

3

4

5

Perfectly

Q

New therapies in HL, conclusions

A

How well did you know this?

1

Not at all

2

3

4

5

Perfectly

Q

WM/LPL DDX

A

How well did you know this?

1

Not at all

2

3

4

5

Perfectly

Q

Special toxicities of drugs used in WM
Ritux
Flu/Clad
Benda
Bortez
Ibrutinib

A

How well did you know this?

1

Not at all

2

3

4

5

Perfectly

Q

1L treatment of WM
2nd line
MAG neuropathy
Bing Neel
Intolerant or refractory to Ibrutinib

A

How well did you know this?

1

Not at all

2

3

4

5

Perfectly

Q

AL amyloid staging tests

A

How well did you know this?

1

Not at all

2

3

4

5

Perfectly

Q

AL amyloid algorithm for workup

A

How well did you know this?

1

Not at all

2

3

4

5

Perfectly

Q

AL amyloid AutoSCT transplant eligibility

A

How well did you know this?

1

Not at all

2

3

4

5

Perfectly

Q

AL amyloid treatment approach

A

How well did you know this?

1

Not at all

2

3

4

5

Perfectly

Q

POEMS diagnostic criteria

A

How well did you know this?

1

Not at all

2

3

4

5

Perfectly

Q

Natural history of MM

A

How well did you know this?

1

Not at all

2

3

4

5

Perfectly

Q

MGUS risk stratification, risk groups, recommended monitoring

A

How well did you know this?

1

Not at all

2

3

4

5

Perfectly

Q

IMWG criteria for MGUS/SMM/MM

A

How well did you know this?

1

Not at all

2

3

4

5

Perfectly

Q

MGRS types
Glomerular vs Tuuloisterstitial vs vascular
Which 2 types deposit everywhere?

A

How well did you know this?

1

Not at all

2

3

4

5

Perfectly

Q

SMM what is the 20-20-20 rule?
Risks of progression

A

How well did you know this?

1

Not at all

2

3

4

5

Perfectly

Q

R-ISS for MM

A

How well did you know this?

1

Not at all

2

3

4

5

Perfectly

Q

MM treatment paradigm, phases of therapy for Fit vs Unfit/not Auto

A

How well did you know this?

1

Not at all

2

3

4

5

Perfectly

Q

Approved therapies in MM over the years

A

How well did you know this?

1

Not at all

2

3

4

5

Perfectly

Q

IMWG response criteria for MM

A

How well did you know this?

1

Not at all

2

3

4

5

Perfectly

Q

R/R MM definition

A

How well did you know this?

1

Not at all

2

3

4

5

Perfectly

Q

Backbones of therapy for MM early relapse

A

How well did you know this?

1

Not at all

2

3

4

5

Perfectly

Q

Plasmacytoma evaluation and therapy algorithm

A

How well did you know this?

1

Not at all

2

3

4

5

Perfectly

Q

Solitary plasmacytoma diagnostic criteria
Solitary bone
Solitary extra medullary
Solitary with minimal marrow involvement
MM

A

How well did you know this?

1

Not at all

2

3

4

5

Perfectly

Q

Plasma cell dyscrasia summary slide

A

How well did you know this?

1

Not at all

2

3

4

5

Perfectly

Q

Deauville scale for PET uptake

A

How well did you know this?

1

Not at all

2

3

4

5

Perfectly

Q

Risk factors for early stage HL
EORTC or GHSG

A

How well did you know this?

1

Not at all

2

3

4

5

Perfectly

Q

CVD incidence in HL survivors for RT or anthracycline

A

How well did you know this?

1

Not at all

2

3

4

5

Perfectly

Q

Frontline chemo regimens in HL
What drugs are in:
A-AVD
ABVD
escBEACOPP

A

How well did you know this?

1

Not at all

2

3

4

5

Perfectly

Q

Longterm followup for HL survivors

A

How well did you know this?

1

Not at all

2

3

4

5

Perfectly

Q

MM pathology images

A

How well did you know this?

1

Not at all

2

3

4

5

Perfectly

Q

DDX of monoclonal gammopathies table

A

Q

MGUS: factors that influence risk of progression

A

Q

Uncommon and rare plasma cell disorders

A

Q

SMM risk factors for progression

A

Q

Symptoms in MM and pathophys

A

Q

Prognostic factors in MM
8 tumor related
5 host related

A

Q

IMWG 2016 relapse definition

A

Q

R-ISS staging for MM

A

Q

IMWG response criteria for MM, complicated table

A

Q

Drug classes and examples in MM

A

Q

R/R MM regimens and trials

A

Q

Dose levels, modifications for frailty, meds in MM
Bortez, Len, Dex, Melph, Fred, Cyclophos

A

Q

Organ involvement in Amyloid, characteristics of each

A

Q

Hematologic response criteria in amyloid

A

Q

Organ response criteria in amyloid

A

Q

Cell of origin for B cell NHLs

A

Q

Lugano criteria staging for NHL

A

Q

GELF criteria for high tumor burden, when to treat

A

Q

FLIPI scoring parameters

A

Q

FL progression/transformation slide
RFs for transformation

A

Q

MALT lymphoma, antigen triggers and which MALT lymphoma?
What translocation to predict resistance of lymphoma to H pylori eradication

A

Q

FL relapses, treatment strategies at each time

A

Q

Mantle cell treatment overview
Fit/young vs old/unfit

A

Q

Summary slide: indolent lymphomas and mantle cell

A

Q

IHC/Flow markers and lineages

A

Q

B cell development, and which malignancies from which cell of origin

A

Q

RFs for NHL

A

Q

T cell development and associated neoplasms

A

Q

Phenotypic markers for different lymphomas

A

Q

DLBCL IPI in rituximab era
Which RFs?

A

APLES
Age>60
PS 2+
LDH
>1 extra nodal site
Stage 3/4

Q

Lugano staging system table

A

Q

FLIPI Score

A

NO-LASH

Q

MIPI score

A

Age
PS
LDH
WBC count

Q

Approach to ND FL patient, by tumor burden and symptoms

A

Q

GELF criteria for high tumor burden

A

Q

iwCLL indications to treat CLL

A

Q

CLL-IPI

A

Q

Frontline BTKi vs Ven+O pros/cons

A

Q

CLL conclusion slide

A

Q

Chronic B cell LPDs, immunophenotypes

A

Q

CLL staging:
Stage, Binet, Rai

A

Q

BCR signalling in CLL, drugs used and their targets

A

Q

CLL-IPI table

A

Q

Treatment algorithm for previously untreated CLL

A

Q

Indications for starting therapy in CLL, and precautions table

A

Q

PTCL types by presentation
Leukemic
Nodal
Other extra nodal

A

Q

Survival by different TCLs
Common vs Uncommon
Best vs worst

A

Q

PTCL initial management

A

Q

ATLL approach by subtype
4 subtypes

A

Q

Mgmt cutaneous TCL
early vs advanced stages

A

Q

IPI for DLBCL

A

Q

Rituximab MOA
What types of cell killing?
Risks of Ritux

A

Q

DLBCL frontline treatment summary

A

Q

RCHOP in DLBCL
Drugs and dosages
How long is a cycle?
Common toxicities

A

Q

Polatuzumab
MOA
What indications?

A

DLBCL untreated
DLBCL r/r

Q

CAR-T vs ASCT in DLBCL
Trials, and which drugs

A

Q

R/R DLBCL
Guide to picking next therapy
R/R >/< 12 mo
prior ASCT
prior CART
ineligible for ASCT/CART

A

Q

3 types of Burkitt Lymphoma, and characteristics
Who, where, EBV status?

A

Q

Burkitt teaching points slide

A

Q

Aggressive B cell lymphoma survivorship/followup

A